90 related articles for article (PubMed ID: 21877752)
61. Detection of HER-3 with an AlGaN/GaN-Based Ion-Sensitive Heterostructure Field Effect Transistor Biosensor.
Wang F; Liu H; Xu Y; Liang Z; Wu Z; Liu Y; Zhang B
Micromachines (Basel); 2023 Jun; 14(6):. PubMed ID: 37374771
[TBL] [Abstract][Full Text] [Related]
62. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma.
Caviglia GP; Abate ML; Rolle E; Carucci P; Armandi A; Rosso C; Olivero A; Ribaldone DG; Tandoi F; Saracco GM; Ciancio A; Bugianesi E; Gaia S
Biology (Basel); 2021 Mar; 10(3):. PubMed ID: 33799723
[TBL] [Abstract][Full Text] [Related]
63. Proteomic Profiling of Paired Interstitial Fluids Reveals Dysregulated Pathways and Salivary NID1 as a Biomarker of Oral Cavity Squamous Cell Carcinoma.
Hsu CW; Chang KP; Huang Y; Liu HP; Hsueh PC; Gu PW; Yen WC; Wu CC
Mol Cell Proteomics; 2019 Oct; 18(10):1939-1949. PubMed ID: 31315917
[TBL] [Abstract][Full Text] [Related]
64. Nomogram predicting extrahepatic metastasis of hepatocellular carcinoma based on commonly available clinical data.
Lee CH; Chang CJ; Lin YJ; Yen CL; Shen CH; Cheng YT; Lin CC; Hsieh SY
JGH Open; 2019 Feb; 3(1):38-45. PubMed ID: 30834339
[TBL] [Abstract][Full Text] [Related]
65. Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells.
Yildiz G
Oncol Lett; 2018 Jul; 16(1):113-122. PubMed ID: 29930714
[TBL] [Abstract][Full Text] [Related]
66. MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3.
Li G; Zhang W; Gong L; Huang X
Oncol Res; 2019 Mar; 27(4):449-458. PubMed ID: 28800792
[TBL] [Abstract][Full Text] [Related]
67. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).
Hayes DA; Kunde DA; Taylor RL; Pyecroft SB; Sohal SS; Snow ET
PLoS One; 2017; 12(6):e0177919. PubMed ID: 28591206
[TBL] [Abstract][Full Text] [Related]
68. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks.
Morris MK; Clarke DC; Osimiri LC; Lauffenburger DA
CPT Pharmacometrics Syst Pharmacol; 2016 Oct; 5(10):544-553. PubMed ID: 27567007
[TBL] [Abstract][Full Text] [Related]
69. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
Buta C; Benabou E; Lequoy M; Régnault H; Wendum D; Meratbene F; Chettouh H; Aoudjehane L; Conti F; Chrétien Y; Scatton O; Rosmorduc O; Praz F; Fartoux L; Desbois-Mouthon C
J Exp Clin Cancer Res; 2016 Aug; 35(1):126. PubMed ID: 27514687
[TBL] [Abstract][Full Text] [Related]
70. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.
Chauhan R; Lahiri N
Biomark Cancer; 2016; 8(Suppl 1):37-55. PubMed ID: 27398029
[TBL] [Abstract][Full Text] [Related]
71. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells.
Cao K; Gong H; Qiu Z; Wen Q; Zhang B; Tang T; Zhou X; Cao T; Wang B; Shi H; Wang R
Tumour Biol; 2016 Aug; 37(8):10375-82. PubMed ID: 26846102
[TBL] [Abstract][Full Text] [Related]
72. Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.
Scheving LA; Zhang X; Stevenson MC; Weintraub MA; Abbasi A; Clarke AM; Threadgill DW; Russell WE
Am J Physiol Gastrointest Liver Physiol; 2015 Dec; 309(12):G942-54. PubMed ID: 26492920
[TBL] [Abstract][Full Text] [Related]
73. Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications.
Wagner M; Wiig H
Front Oncol; 2015; 5():115. PubMed ID: 26075182
[TBL] [Abstract][Full Text] [Related]
74. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
[TBL] [Abstract][Full Text] [Related]
75. Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling.
Wei S; Suryani Y; Gowda GA; Skill N; Maluccio M; Raftery D
Metabolites; 2012 Oct; 2(4):701-16. PubMed ID: 24957758
[TBL] [Abstract][Full Text] [Related]
76. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.
Berasain C; Avila MA
J Gastroenterol; 2014 Jan; 49(1):9-23. PubMed ID: 24318021
[TBL] [Abstract][Full Text] [Related]
77. Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.
Fye HK; Wright-Drakesmith C; Kramer HB; Camey S; Nogueira da Costa A; Jeng A; Bah A; Kirk GD; Sharif MI; Ladep NG; Okeke E; Hainaut P; Taylor-Robinson SD; Kessler BM; Mendy ME
PLoS One; 2013; 8(7):e68381. PubMed ID: 23935864
[TBL] [Abstract][Full Text] [Related]
78. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis.
Hsieh SY; He JR; Yu MC; Lee WC; Chen TC; Lo SJ; Bera R; Sung CM; Chiu CT
J Proteome Res; 2011 Oct; 10(10):4715-24. PubMed ID: 21877752
[TBL] [Abstract][Full Text] [Related]
79. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
80. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.
Wang W; Zhao LJ; Wang Y; Tao QY; Feitelson MA; Zhao P; Ren H; Qi ZT
Cancer Biomark; 2011-2012; 11(1):29-39. PubMed ID: 22820138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
